Abstract: The present invention is directed to a device comprising a fabric substrate layer having a dividing line horizontal to the length of the fabric substrate layer that divides a first part coated with a skin-safe adhesive layer on one side and a second part that is not covered by the skin-safe adhesive layer; and methods of application therefrom.

Abstract: The present invention is directed to a device comprising a fabric substrate layer having a dividing line horizontal to the length of the fabric substrate layer that divides a first part coated with a skin-safe adhesive layer on one side and a second part that is not covered by the skin-safe adhesive layer; and methods of application therefrom.

Abstract: A medical system includes a wearable medical device configured to be worn by a patient, remote server(s), and a mobile device. The mobile device includes at least one processor and a display, the at least one processor being configured to establish communication between the mobile device, the wearable medical device, and the remote server(s) when the mobile device is powered on and within a predetermined range of the wearable medical device. The at least one processor is further configured to provide an interactive survey on the display to receive one or more user inputs, update a graphical user interface on the display based on the one or more user inputs, and cause one or more patient engagement features to be displayed on the display. Upon establishing communication between the mobile device, the wearable medical device, and the remote server(s), patient data is transmitted to the remote server(s).

Abstract: The invention relates to the identification of the ovo-like zinc finger 1 (OVOL1) as a new biomarker of moderate to severe acne. The invention also relates to products and methods for detecting, diagnosing, staging, treating or monitoring the course of acne in a human subject.

Abstract: The invention relates to the identification of Adaptor-Related Protein Complex 5, subunit 1 (AP5B1) as a biomarker of moderate to severe acne. The invention also relates to products and methods for detecting, diagnosing, staging, treating or monitoring the course of acne in a human subject.

Abstract: The present invention provides, inter alia, crystals of the MEK1 polypeptide which are particularly useful for structure based drug design as well as methods of use thereof.

Abstract: The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-? synthesis; iii) an inhibitor of membrane-bound TNF-?; iv) an inhibitor of a natural receptor of TNF-?; v) an inhibitor of NO synthase, vi) an inhibitor of PLA2 enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-I, IGF-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase.

Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.

Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.

Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.

Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.

Abstract: A method of synthesizing a compound of formula I: comprising the step of reacting a moiety of formula II: with a moiety of formula III: in compressed carbon dioxide in the presence of a transition metal catalyst and a base, wherein L is a labile leaving group; RN1 is optionally substituted C5-20 aryl; RN2 is selected from optionally substituted C5-20aryl, optionally substituted C3-20 heterocyclyl, optionally substituted C3-7 alkyl, and optionally substituted sulfonyl; RN3 is selected from H and optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl; or RN2 and RN3 together with the nitrogen atom to which they are attached form optionally substituted nitrogen-containing C3-20 heterocylyl or C5-20 heteroaryl; and R1 R2 and R3 are independently selected from optionally substituted C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, hydroxy, halo, amino and C1-7 alkoxy, or two of R1, R2 and R3, together with the silicon atom to which they are attached, may form a silicon containing C5-7 heterocyclyl group.

Abstract: The present invention provides novel calibration devices for use with fluorescent nanocrystal labels. Methods of preparing and using the calibration devices are also provided. Monodispersed populations of nanocrystals are deposited on surfaces. The monodispersed populations are obtained by dissolving the nanocrystals in a polar solvent.

Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.

Abstract: The present invention is directed to novel compounds and a process for augmenting or imparting a flavor enhancement effect or modifying the perception of one or more of the five basic taste qualities sweet, sour, salt, bitter and umami, to a foodstuff, chewing gum, medicinal product, toothpaste, alcoholic beverage, aqueous beverage, snack, sauce or soup comprising the step of adding to a foodstuff, chewing gum, medicinal product, toothpaste, alcoholic beverage, aqueous beverage, snack, sauce or soup a flavor enhancement or modification of basic taste quality augmenting, enhancing or imparting quantity and concentration of at least one N-substituted unsaturated alkyl amide defined according to the structures:

Abstract: The present invention provides a method of diagnosing the presence or severity of tissue fibrosis in an individual by detecting ?2-macroglobulin (?2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of tissue fibrosis in the individual based on the presence or level of ?2-MG, HA and TIMP-1.

Abstract: The present invention relates to injecting a cycline compound into a diseased intervertebral disc.

Abstract: The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-? synthesis; iii) an inhibitor of membrane-bound TNF-?; iv) an inhibitor of a natural receptor of TNF-?; v) an inhibitor of NO synthase, vi) an inhibitor of PLA2 enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-I, IGF-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase.

Abstract: A novel compound 4H-indeno[4,5-D]-1,3-dioxole, 3A,5,6,7,8,8B-hexahydro-2,2,6,6,7,8,8-heptamethyl is dislosed as well as the use of the compound as a fragrance chemical. The fragrance compound is suitable for use in creating fragrances, and scents in items such as perfumes, colognes and personal care products.

Abstract: The present invention relates to injecting a high specificity p38 kinase inhibitor into a diseased intervertebral disc.